Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cardioversion, Ablation or Pace and Ablate for Persistent Atrial Fibrillation in Over 65s - The CAPAPAF-65 Study

NCT02528604 is registered in ClinicalTrials.gov with Eastbourne General Hospital as lead sponsor.

NCT NCT02528604
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02528604 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cardioversion, Ablation or Pace and Ablate for Persistent Atrial Fibrillation in Over 65s - The CAPAPAF-65 Study
Lead sponsor
Eastbourne General Hospital
Phase
Phase 4
Overall status
Completed
Start date
July 31, 2016
Completion date
September 30, 2018
Enrollment
75 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

persistent atrial fibrillation